Determination of the Preventive Effect of Desmopressin Acetate on the incidence of bleeding complications following kidney biopsy in patients with renal disease

Phase 2

Conditions: Chronic kidney patients.
Chronic kidney disease, unspecified
N18.9

Registration Number: IRCT20090701002112N3

Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 146

Inclusion Criteria

People 18 years and older
15=GFR=90 cc/min/1.73 m2 according MDRD formula

Exclusion Criteria

Disrupted coagulation profile (including disruption in any of the PT tests, INR, PTT, and platelet counts are less than 50000
Systrelic Blood Pressure Time Biopsy less than160mmhg
Diastolic BP Time to do biopsy less than100mmhg
Single kidney
Kidney cancer
Renal hydronephrosis
Renal Pyrenophore
Small size Significant kidneys in ultrasound
Severe obesity
Hemoglobin less than 11
Sodium concentration in serum less than 120
Primary phenotypes
Renal transplantation
Multiple cysts in both kidneys

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hematoma. Timepoint: Immediately after receiving a kidney biopsy specimen and 24 hours later, and in the event of a hematoma, 48-72 hours later. Method of measurement: Ultrasonography.

Secondary Outcome Measures

Name	Time	Method
Hematuria. Timepoint: After biopsy. Method of measurement: View at any time urinating.;Vital signs l (blood pressure and heart rate). Timepoint: Every 15 minutes for 2 hours, then every 1 hour for 4 hours, then every 2 hours for 6 hours, and then every 4 hours. Method of measurement: Device.;Flank pain. Timepoint: Follow up on every visit. Method of measurement: Physical exam.;Biochemical Factors (Sodium, Hemoglobin, Hematocrit). Timepoint: 24 hours after biopsy. Method of measurement: Blood test.